Phase I/IIa Study of RNActive-Derived Therapeutic Vaccine in Metastatic Hormone Refractory Prostate Cancer.

Trial Profile

Phase I/IIa Study of RNActive-Derived Therapeutic Vaccine in Metastatic Hormone Refractory Prostate Cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 03 Apr 2012

At a glance

  • Drugs CV 9103 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 29 Mar 2012 Actual patient number changed from 10 to 6 as reported by ClinicalTrials.gov.
    • 22 Jul 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 10 Feb 2011 Planned end date changed from 1 Sep 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top